{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:23:54Z","timestamp":1791822234935,"version":"4.3.4"},"reference-count":133,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008811","name":"Centre of Excellence for Electromaterials Science, Australian Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008811","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.tips.2021.01.004","type":"journal-article","created":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T01:17:09Z","timestamp":1613870229000},"page":"239-254","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Emerging Therapeutic Applications for Fumarates"],"prefix":"10.1016","volume":"42","author":[{"given":"Ayla","family":"Hoogendoorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas D.","family":"Avery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahe","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Bursill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Abell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Grace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2021.01.004_bb0005","series-title":"Assessment Report on Fumaria officinalis L., herba","author":"Committee on Herbal Medicinal Products (HMPC) - EMA","year":"2011"},{"key":"10.1016\/j.tips.2021.01.004_bb0010","first-page":"103","article-title":"Treatment of psoriasis vulgaris","volume":"13","author":"Schweckendiek","year":"1959","journal-title":"Med. Monatsschr."},{"key":"10.1016\/j.tips.2021.01.004_bb0015","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1468-1331.2006.01292.x","article-title":"Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study","volume":"13","author":"Schimrigk","year":"2006","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.tips.2021.01.004_bb0020","first-page":"793","article-title":"Dimethyl fumarate - only an anti-psoriatic medication?","volume":"10","author":"Meissner","year":"2012","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"10.1016\/j.tips.2021.01.004_bb0025","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2125.2004.02145.x","article-title":"Pharmacokinetics of oral fumarates in healthy subjects","volume":"58","author":"Litjens","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.tips.2021.01.004_bb0030","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1471-2210-4-22","article-title":"In vitro pharmacokinetics of anti-psoriatic fumaric acid esters","volume":"4","author":"Litjens","year":"2004","journal-title":"BMC Pharmacol."},{"key":"10.1016\/j.tips.2021.01.004_bb0035","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00403-010-1061-4","article-title":"Pharmacokinetics of anti-psoriatic fumaric acid esters in psoriasis patients","volume":"302","author":"Rostami-Yazdi","year":"2010","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.tips.2021.01.004_bb0040","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00403-013-1332-y","article-title":"Detection of fumarate-glutathione adducts in the portal vein blood of rats: evidence for rapid dimethylfumarate metabolism","volume":"305","author":"Dibbert","year":"2013","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.tips.2021.01.004_bb0045","series-title":"2015 Annual Meeting of the Consortium of the Multiple Sclerosis Centers","article-title":"Safety, Tolerability, and Pharmacokinetics of ALKS 8700, a Novel Oral Therapy for Relapsing-Remitting Multiple Sclerosis, in Healthy Subjects","author":"Hunt","year":"2015"},{"key":"10.1016\/j.tips.2021.01.004_bb0050","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.80.7_supplement.P05.189","article-title":"Favorable metabolism and pharmacokinetics of formulations of XP23829, a novel fumaric acid ester, in healthy subjects","volume":"80","author":"Lissin","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2021.01.004_bb0055","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/1523-1747.ep12358715","article-title":"Effects of monomethylfumarate on human granulocytes","volume":"101","author":"Nibbering","year":"1993","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.tips.2021.01.004_bb0060","article-title":"Breaking the cycle: reversal of flux in the tricarboxylic acid cycle by dimethyl fumarate. Neurol. Neuroimmunol","volume":"6","author":"Gafson","year":"2019","journal-title":"NeuroInflammation"},{"key":"10.1016\/j.tips.2021.01.004_bb0065","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/jid.2008.197","article-title":"Detection of metabolites of fumaric acid esters in human urine: implications for their mode of action","volume":"129","author":"Rostami-Yazdi","year":"2009","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.tips.2021.01.004_bb0070","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.bmc.2006.09.053","article-title":"Reactivity of dimethyl fumarate and methylhydrogen fumarate towards glutathione and N-acetyl-l-cysteine-preparation of S-substituted thiosuccinic acid esters","volume":"15","author":"Schmidt","year":"2007","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.tips.2021.01.004_bb0075","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000247856","article-title":"Fumaric acid therapy in psoriasis: a double-blind comparison between fumaric acid compound therapy and monotherapy with dimethylfumaric acid ester","volume":"181","author":"Nieboer","year":"1990","journal-title":"Dermatology"},{"key":"10.1016\/j.tips.2021.01.004_bb0080","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00403-018-1825-9","article-title":"Dimethyl fumarate (DMF) vs. monoethyl fumarate (MEF) salts for the treatment of plaque psoriasis: a review of clinical data","volume":"310","author":"Landeck","year":"2018","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.tips.2021.01.004_bb0085","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/bdd.364","article-title":"Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid esters","volume":"24","author":"Werdenberg","year":"2003","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.tips.2021.01.004_bb0090","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.540","article-title":"No evidence for interactions of dimethylfumarate (DMF) and its main metabolite monomethylfumarate (MMF) with human cytochrome P450 (CYP) enzymes and the P-glycoprotein (P-gp) drug transporter","volume":"7","author":"Aubets","year":"2019","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.tips.2021.01.004_bb0095","series-title":"Cerebrospinal Fluid Penetration of Dimethyl Fumarate in Patients with Multiple Sclerosis \u2013 Abstract","first-page":"P904","author":"Penner","year":"2018"},{"key":"10.1016\/j.tips.2021.01.004_bb0100","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"Reagan-Shaw","year":"2008","journal-title":"FASEB J."},{"key":"10.1016\/j.tips.2021.01.004_bb0105","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1096\/fj.14-269043","article-title":"Translating dosages from animal models to human clinical trials-revisiting body surface area scaling","volume":"29","author":"Blanchard","year":"2015","journal-title":"FASEB J."},{"key":"10.1016\/j.tips.2021.01.004_bb0110","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1073\/pnas.1603907113","article-title":"Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2","volume":"113","author":"Schulze-Topphoff","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2021.01.004_bb0115","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1089\/ars.2015.6622","article-title":"Pharmacodynamics of dimethyl fumarate are tissue specific and involve NRF2-dependent and -independent mechanisms","volume":"24","author":"Brennan","year":"2016","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.tips.2021.01.004_bb0120","doi-asserted-by":"crossref","first-page":"6332","DOI":"10.1523\/JNEUROSCI.0426-16.2016","article-title":"Distinct Nrf2 signaling mechanisms of fumaric acid esters and their role in neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced experimental Parkinson\u2019s-like disease","volume":"36","author":"Ahuja","year":"2016","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tips.2021.01.004_bb0125","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1126\/science.aan4665","article-title":"Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity","volume":"360","author":"Kornberg","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.tips.2021.01.004_bb0130","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/brain\/awq386","article-title":"Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway","volume":"134","author":"Linker","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.tips.2021.01.004_bb0135","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1042\/AN20100033","article-title":"The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1","volume":"3","author":"Lin","year":"2011","journal-title":"ASN Neuro"},{"key":"10.1016\/j.tips.2021.01.004_bb0140","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1124\/jpet.111.190132","article-title":"Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway","volume":"341","author":"Scannevin","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.tips.2021.01.004_bb0145","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41573-018-0008-x","article-title":"Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases","volume":"18","author":"Cuadrado","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tips.2021.01.004_bb0150","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1152\/physrev.00023.2017","article-title":"The KEAP1-NRF2 system: a thiol-based sensor-effector apparatus for maintaining redox homeostasis","volume":"98","author":"Yamamoto","year":"2018","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.tips.2021.01.004_bb0155","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12974-018-1125-5","article-title":"Dimethyl fumarate attenuates reactive microglia and long-term memory deficits following systemic immune challenge","volume":"15","author":"Paraiso","year":"2018","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.tips.2021.01.004_bb0160","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.bcp.2008.07.017","article-title":"Activation of Nrf2-antioxidant signaling attenuates NF\u03baB-inflammatory response and elicits apoptosis","volume":"76","author":"Li","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.tips.2021.01.004_bb0165","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1042\/BST20150014","article-title":"Dissecting molecular cross-talk between Nrf2 and NF-\u03baB response pathways","volume":"43","author":"Wardyn","year":"2015","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.tips.2021.01.004_bb0170","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/cr.2010.178","article-title":"Crosstalk of reactive oxygen species and NF-\u03baB signaling","volume":"21","author":"Morgan","year":"2011","journal-title":"Cell Res."},{"key":"10.1016\/j.tips.2021.01.004_bb0175","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.freeradbiomed.2013.07.028","article-title":"Up-down regulation of HO-1 and iNOS gene expressions by ethyl pyruvate via recruiting p300 to Nrf2 and depriving it from p65","volume":"65","author":"Kim","year":"2013","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.tips.2021.01.004_bb0180","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/j.bcp.2010.07.014","article-title":"Signaling to heme oxygenase-1 and its anti-inflammatory therapeutic potential","volume":"80","author":"Paine","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.tips.2021.01.004_bb0185","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.molmed.2008.12.004","article-title":"Heme oxygenase-1: from biology to therapeutic potential","volume":"15","author":"Soares","year":"2009","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.tips.2021.01.004_bb0190","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.bbrc.2008.08.041","article-title":"The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist","volume":"375","author":"Tang","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.tips.2021.01.004_bb0195","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm824","article-title":"PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect","volume":"9","author":"Tunaru","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2021.01.004_bb0200","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.tem.2016.11.007","article-title":"Hydroxy-carboxylic acid receptor actions in metabolism","volume":"28","author":"Offermanns","year":"2017","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.tips.2021.01.004_bb0205","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1007\/s00018-011-0757-8","article-title":"Cyclic AMP: a selective modulator of NF-\u03baB action","volume":"68","author":"Gerlo","year":"2011","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.tips.2021.01.004_bb0210","first-page":"1","article-title":"Activated niacin receptor HCA2 inhibits chemoattractant-mediated macrophage migration via G\u03b2\u03b3\/PKC\/ERK1\/2 pathway and heterologous receptor desensitization","volume":"7","author":"Shi","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tips.2021.01.004_bb0215","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11883-013-0325-9","article-title":"GPR109A and vascular inflammation","volume":"15","author":"Chai","year":"2013","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.tips.2021.01.004_bb0220","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00401-015-1422-3","article-title":"Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS","volume":"130","author":"Parodi","year":"2015","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.tips.2021.01.004_bb0225","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12974-019-1411-x","article-title":"AMPK activation attenuates inflammatory pain through inhibiting NF-\u03baB activation and IL-1\u03b2 expression","volume":"16","author":"Xiang","year":"2019","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.tips.2021.01.004_bb0230","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1172\/JCI36806","article-title":"\u03b2-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice","volume":"119","author":"Walters","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tips.2021.01.004_bb0235","doi-asserted-by":"crossref","first-page":"8603","DOI":"10.1073\/pnas.0402851101","article-title":"\u03b2-Arrestin inhibits NF-\u03baB activity by means of its interaction with the NF-\u03baB inhibitor I\u03baB\u03b1","volume":"101","author":"Witherow","year":"2004","journal-title":"Proc. Natl Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2021.01.004_bb0240","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1084\/jem.20151570","article-title":"Immunometabolism governs dendritic cell and macrophage function","volume":"213","author":"O\u2019Neill","year":"2016","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.tips.2021.01.004_bb0245","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"James","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2021.01.004_bb0250","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2021.01.004_bb0255","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/S0140-6736(08)61619-0","article-title":"Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study","volume":"372","author":"Kappos","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2021.01.004_bb0260","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40263-020-00700-0","article-title":"Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing\u2013remitting multiple sclerosis: results from the randomized, double-blind, phase III EVOLVE-MS-2 study","volume":"34","author":"Naismith","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.tips.2021.01.004_bb0265","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/ALN.0000000000003077","article-title":"Oral dimethyl fumarate reduces peripheral neuropathic pain in rodents via NFE2L2 antioxidant signaling","volume":"132","author":"Li","year":"2020","journal-title":"Anesthesiology"},{"key":"10.1016\/j.tips.2021.01.004_bb0270","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1096\/fj.201801033R","article-title":"Ketones and pain: unexplored role of hydroxyl carboxylic acid receptor type 2 in the pathophysiology of neuropathic pain","volume":"33","author":"Boccella","year":"2019","journal-title":"FASEB J."},{"key":"10.1016\/j.tips.2021.01.004_bb0275","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1248\/bpb.b18-00855","article-title":"Dimethyl fumarate attenuates oxaliplatin-induced peripheral neuropathy without affecting the anti-tumor activity of oxaliplatin in rodents","volume":"42","author":"Miyagi","year":"2019","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.tips.2021.01.004_bb0280","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jphs.2018.06.008","article-title":"Dimethyl fumarate ameliorates chemotherapy agent-induced neurotoxicity in vitro","volume":"137","author":"Kawashiri","year":"2018","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.tips.2021.01.004_bb0285","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nri3621","article-title":"Pathological pain and the neuroimmune interface","volume":"14","author":"Grace","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tips.2021.01.004_bb0290","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.tins.2016.10.003","article-title":"Nitroxidative signaling mechanisms in pathological pain","volume":"39","author":"Grace","year":"2016","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.tips.2021.01.004_bb0295","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1523\/JNEUROSCI.1650-20.2020","article-title":"The neuroimmunology of chronic pain: from rodents to humans","volume":"41","author":"Grace","year":"2021","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tips.2021.01.004_bb0300","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1097\/j.pain.0000000000001042","article-title":"Monomethyl fumarate (MMF) inhibits pain behaviors and amygdala activity in a rat arthritis model","volume":"158","author":"Kim","year":"2017","journal-title":"Pain"},{"key":"10.1016\/j.tips.2021.01.004_bb0305","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12974-020-01736-1","article-title":"Dimethyl fumarate alleviates the nitroglycerin (NTG)-induced migraine in mice","volume":"17","author":"Casili","year":"2020","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.tips.2021.01.004_bb0310","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/j.pain.0000000000001138","article-title":"Sensory profiling in animal models of neuropathic pain: a call for back-translation","volume":"159","author":"Rice","year":"2018","journal-title":"Pain"},{"key":"10.1016\/j.tips.2021.01.004_bb0315","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1111\/bph.12645","article-title":"Improving the translation of analgesic drugs to the clinic: animal models of neuropathic pain","volume":"171","author":"Percie Du Sert","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.tips.2021.01.004_bb0320","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jpain.2017.12.261","article-title":"Inflammatory and neuropathic pain from bench to bedside: what went wrong?","volume":"19","author":"Yezierski","year":"2018","journal-title":"J. Pain"},{"key":"10.1016\/j.tips.2021.01.004_bb0325","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.neubiorev.2019.03.009","article-title":"Pros and cons of clinically relevant methods to assess pain in rodents","volume":"100","author":"Tappe-Theodor","year":"2019","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.tips.2021.01.004_bb0330","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nrn2606","article-title":"Animal models of pain: progress and challenges","volume":"10","author":"Mogil","year":"2009","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.tips.2021.01.004_bb0335","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1089\/ars.2016.6800","article-title":"The neuroprotective effect of dimethyl fumarate in an MPTP-mouse model of Parkinson\u2019s disease: involvement of reactive oxygen species\/nuclear factor-\u03baB\/nuclear transcription factor related to NF-E2","volume":"27","author":"Campolo","year":"2017","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.tips.2021.01.004_bb0340","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.neuroscience.2014.11.047","article-title":"Dimethyl fumarate attenuates 6-OHDA-induced neurotoxicity in SH-SY5Y cells and in animal model of Parkinson\u2019s disease by enhancing Nrf2 activity","volume":"286","author":"Jing","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.tips.2021.01.004_bb0345","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1089\/ars.2015.6549","article-title":"Repurposing the NRF2 activator dimethyl fumarate as therapy against synucleinopathy in Parkinson\u2019s disease","volume":"25","author":"Lastres-Becker","year":"2016","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.tips.2021.01.004_bb0350","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1476-5381.2011.01426.x","article-title":"Animal models of Parkinson\u2019s disease: a source of novel treatments and clues to the cause of the disease","volume":"164","author":"Duty","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.tips.2021.01.004_bb0355","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nrn.2017.75","article-title":"Animal models of \u03b1-synucleinopathy for Parkinson disease drug development","volume":"18","author":"Koprich","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.tips.2021.01.004_bb0360","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.bbr.2016.04.012","article-title":"Dimethyl fumarate attenuates intracerebroventricular streptozotocin-induced spatial memory impairment and hippocampal neurodegeneration in rats","volume":"308","author":"Majkutewicz","year":"2016","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.tips.2021.01.004_bb0365","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.brainres.2018.02.016","article-title":"Age-dependent effects of dimethyl fumarate on cognitive and neuropathological features in the streptozotocin-induced rat model of Alzheimer\u2019s disease","volume":"1686","author":"Majkutewicz","year":"2018","journal-title":"Brain Res."},{"key":"10.1016\/j.tips.2021.01.004_bb0370","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00401-016-1662-x","article-title":"Alzheimer\u2019s disease: experimental models and reality","volume":"133","author":"Drummond","year":"2017","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.tips.2021.01.004_bb0375","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006320","article-title":"Animal models of Alzheimer disease","volume":"2","author":"LaFerla","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.tips.2021.01.004_bb0380","series-title":"Neuroprotection in Alzheimer\u2019s Disease","first-page":"31","article-title":"Animal models of Alzheimer\u2019s disease","author":"Amram","year":"2017"},{"key":"10.1016\/j.tips.2021.01.004_bb0385","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.expneurol.2017.06.011","article-title":"Fumarate decreases edema volume and improves functional outcome after experimental stroke","volume":"295","author":"Clausen","year":"2017","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.tips.2021.01.004_bb0390","doi-asserted-by":"crossref","first-page":"375","DOI":"10.21037\/atm.2020.02.10","article-title":"Neuroprotective effect of dimethyl fumarate on cognitive impairment induced by ischemic stroke","volume":"8","author":"Hou","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.tips.2021.01.004_bb0395","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S1474-4422(12)70104-7","article-title":"Intracerebral haemorrhage: mechanisms of injury and therapeutic targets","volume":"11","author":"Keep","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.tips.2021.01.004_bb0400","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.nbd.2015.07.001","article-title":"Dimethyl fumarate confers neuroprotection by casein kinase 2 phosphorylation of Nrf2 in murine intracerebral hemorrhage","volume":"82","author":"Iniaghe","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.tips.2021.01.004_bb0405","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1161\/STROKEAHA.115.009398","article-title":"Dimethyl fumarate protects brain from damage produced by intracerebral hemorrhage by mechanism involving Nrf2","volume":"46","author":"Zhao","year":"2015","journal-title":"Stroke"},{"key":"10.1016\/j.tips.2021.01.004_bb0410","article-title":"Are researchers moving away from animal models as a result of poor clinical translation in the field of stroke? An analysis of opinion papers","volume":"4","author":"Pound","year":"2020","journal-title":"BMJ Open Sci."},{"key":"10.1016\/j.tips.2021.01.004_bb0415","doi-asserted-by":"crossref","first-page":"R165","DOI":"10.1152\/ajpregu.00163.2017","article-title":"Large animal models of stroke and traumatic brain injury as translational tools","volume":"315","author":"Sorby-Adams","year":"2018","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.tips.2021.01.004_bb0420","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00403-015-1541-7","article-title":"Impact of fumaric acid esters on cardiovascular risk factors and depression in psoriasis: a prospective pilot study","volume":"307","author":"Schmieder","year":"2015","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.tips.2021.01.004_bb0425","article-title":"Disparate effects of adalimumab and fumaric acid esters on cardiovascular risk factors in psoriasis patients: results from a prospective, randomized, observer-blinded head-to-head trial","author":"Holzer","year":"2020","journal-title":"J. Eur. Acad. Dermatology Venereol."},{"key":"10.1016\/j.tips.2021.01.004_bb0430","first-page":"1","article-title":"HDL-cholesterol elevation associated with fingolimod and dimethyl fumarate therapies in multiple sclerosis","volume":"5","author":"Blumenfeld Kan","year":"2019","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.tips.2021.01.004_bb0435","doi-asserted-by":"crossref","first-page":"7966","DOI":"10.12659\/MSM.918951","volume":"25","author":"Luo","year":"2019","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.tips.2021.01.004_bb0440","first-page":"153","article-title":"Antioxidant and anti-inflammatory effects of dimethyl fumarate in hypercholesterolemic rabbits","volume":"4","author":"Nour","year":"2017","journal-title":"Egypt. J. Basic Appl. Sci."},{"key":"10.1016\/j.tips.2021.01.004_bb0445","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.redox.2014.06.003","article-title":"Dimethylfumarate attenuates restenosis after acute vascular injury by cell-specific and Nrf2-dependent mechanisms","volume":"2","author":"Oh","year":"2014","journal-title":"Redox Biol."},{"key":"10.1016\/j.tips.2021.01.004_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117887","article-title":"Dimethyl fumarate ameliorates diabetes-associated vascular complications through ROS-TXNIP-NLRP3 inflammasome pathway","volume":"256","author":"Amin","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.tips.2021.01.004_bb0455","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.vph.2014.06.007","article-title":"Activation of Nrf2 by dimethyl fumarate improves vascular calcification","volume":"63","author":"Ha","year":"2014","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.tips.2021.01.004_bb0460","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/ATVBAHA.111.237693","article-title":"Animal models of atherosclerosis","volume":"32","author":"Getz","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.tips.2021.01.004_bb0465","first-page":"501","article-title":"Animal models for plaque rupture: a biomechanical assessment","volume":"115","author":"van der Heiden","year":"2015","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.tips.2021.01.004_bb0470","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/jphp.13000","article-title":"Dimethyl fumarate interferes with MyD88-dependent toll-like receptor signalling pathway in isoproterenol-induced cardiac hypertrophy model","volume":"70","author":"Ahmed","year":"2018","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.tips.2021.01.004_bb0475","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.toxlet.2018.01.020","article-title":"Protection by dimethyl fumarate against diabetic cardiomyopathy in type 1 diabetic mice likely via activation of nuclear factor erythroid-2 related factor 2","volume":"287","author":"Hu","year":"2018","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.tips.2021.01.004_bb0480","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1177\/2047487319870344","article-title":"Oxidative stress and inflammation in the evolution of heart failure: from pathophysiology to therapeutic strategies","volume":"27","author":"Aimo","year":"2020","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.tips.2021.01.004_bb0485","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/jdv.15218","article-title":"Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus","volume":"32","author":"Mrowietz","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.tips.2021.01.004_bb0490","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1185\/03007995.2013.849236","article-title":"BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety","volume":"30","author":"Fox","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.tips.2021.01.004_bb0495","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.clinthera.2015.03.028","article-title":"Effect of aspirin pretreatment or slow dose titration on flushing and gastrointestinal events in healthy volunteers receiving delayed-release dimethyl fumarate","volume":"37","author":"O\u2019Gorman","year":"2015","journal-title":"Clin. Ther."},{"key":"10.1016\/j.tips.2021.01.004_bb0500","series-title":"Vitalis Receives Orphan Drug Designation for Diroximel Fumarate and Monomethyl Fumarate, in Combination with VTS-Aspirin, for Multiple Sclerosis Patients Who Experience Fumarate Flush","author":"Vitalis Pharmaceuticals","year":"2020"},{"key":"10.1016\/j.tips.2021.01.004_bb0505","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1007\/s12325-019-01085-3","article-title":"Improving the gastrointestinal tolerability of fumaric acid esters: early findings on gastrointestinal events with diroximel fumarate in patients with relapsing-remitting multiple sclerosis from the phase 3, open-label EVOLVE-MS-1 study","volume":"36","author":"Palte","year":"2019","journal-title":"Adv. Ther."},{"key":"10.1016\/j.tips.2021.01.004_bb0510","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.msard.2014.03.003","article-title":"Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: experiences of an international panel","volume":"3","author":"Phillips","year":"2014","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.tips.2021.01.004_bb0515","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1212\/CPJ.0000000000000238","article-title":"Characterizing absolute lymphocyte count profiles in dimethyl fumarate treated patients with MS patient management considerations","volume":"6","author":"Fox","year":"2016","journal-title":"Neurol. Clin. Pract."},{"key":"10.1016\/j.tips.2021.01.004_bb0520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fneur.2018.00005","article-title":"Emerging understanding of the mechanism of action for dimethyl fumarate in the treatment of multiple sclerosis","volume":"9","author":"Mills","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/j.tips.2021.01.004_bb0525","series-title":"Bafiertram (Monomethyl Fumarate) - Highlight of Prescribing Information","author":"FDA","year":"2013"},{"key":"10.1016\/j.tips.2021.01.004_bb0530","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1002\/med.21567","article-title":"Dimethyl fumarate, a two-edged drug: current status and future directions","volume":"39","author":"Saidu","year":"2019","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.tips.2021.01.004_bb0535","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1002\/cam4.2101","article-title":"Nrf2 in cancers: a double-edged sword","volume":"8","author":"Wu","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.tips.2021.01.004_bb0540","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1021\/acschemneuro.6b00428","article-title":"Enhanced brain delivery of dimethyl fumarate employing tocopherol-acetate-based nanolipidic carriers: evidence from pharmacokinetic, biodistribution, and cellular uptake studies","volume":"8","author":"Kumar","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.tips.2021.01.004_bb0545","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1080\/09205063.2019.1680929","article-title":"Long term multiple sclerosis drug delivery using dendritic polyglycerol flower-like microspheres","volume":"31","author":"da Silva","year":"2020","journal-title":"J. Biomater. Sci. Polym. Ed."},{"key":"10.1016\/j.tips.2021.01.004_bb0550","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1021\/acsbiomaterials.7b01031","article-title":"Lysine-based C60-fullerene nanoconjugates for monomethyl fumarate delivery: a novel nanomedicine for brain cancer cells","volume":"4","author":"Kumar","year":"2018","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.tips.2021.01.004_bb0555","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/exd.13548","article-title":"A review of the mechanisms of action of dimethylfumarate in the treatment of psoriasis","volume":"27","author":"Br\u00fcck","year":"2018","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.tips.2021.01.004_bb0560","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1084\/jem.20100977","article-title":"Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells","volume":"208","author":"Ghoreschi","year":"2011","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.tips.2021.01.004_bb0565","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ajpath.2019.10.022","article-title":"Nuclear factor erythroid 2-related factor 2 (Nrf2) regulates epidermal keratinization under psoriatic skin inflammation","volume":"190","author":"Ogawa","year":"2020","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.tips.2021.01.004_bb0570","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-11139-3","article-title":"Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes","volume":"10","author":"Carlstr\u00f6m","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2021.01.004_bb0575","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-13731-z","article-title":"IL-17+ CD8+ T cell suppression by dimethyl fumarate associates with clinical response in multiple sclerosis","volume":"10","author":"L\u00fcckel","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2021.01.004_bb0580","doi-asserted-by":"crossref","first-page":"P15","DOI":"10.1186\/1479-5876-9-S2-P15","article-title":"Treatment of lupus erythematosus with fumaric acid ester derivatives: two case-reports","volume":"9","author":"Balak","year":"2011","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.tips.2021.01.004_bb0585","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1212\/WNL.0b013e3182697e70","article-title":"Blood-brain barrier, reperfusion injury, and hemorrhagic transformation in acute ischemic stroke","volume":"79","author":"Khatri","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2021.01.004_bb0590","series-title":"Mechanisms of Vascular Disease: A Reference Book for Vascular Specialists","first-page":"331","article-title":"Pathophysiology of reperfusion injury","author":"Cowled","year":"2011"},{"key":"10.1016\/j.tips.2021.01.004_bb0595","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/nm.2507","article-title":"Ischemia and reperfusion-from mechanism to translation","volume":"17","author":"Eltzschig","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2021.01.004_bb0600","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-016-0733-1","article-title":"Fumarate modulates the immune\/inflammatory response and rescues nerve cells and neurological function after stroke in rats","volume":"13","author":"Lin","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.tips.2021.01.004_bb0605","first-page":"108","article-title":"Neuroprotective effect of dimethyl fumarate in stroke: the role of nuclear factor erythroid 2-related factor 2","volume":"18","author":"Safari","year":"2019","journal-title":"Iran. J. Neurol."},{"key":"10.1016\/j.tips.2021.01.004_bb0610","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s12975-016-0496-0","article-title":"Dimethyl fumarate and monomethyl fumarate promote post-ischemic recovery in mice","volume":"7","author":"Yao","year":"2016","journal-title":"Transl. Stroke Res."},{"key":"10.1016\/j.tips.2021.01.004_bb0615","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.expneurol.2015.02.022","article-title":"Dimethyl fumarate attenuates cerebral edema formation by protecting the blood-brain barrier integrity","volume":"266","author":"Kunze","year":"2015","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.tips.2021.01.004_bb0620","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/3803657","article-title":"Protective effects of L-malate against myocardial ischemia\/reperfusion injury in rats","volume":"2016","author":"Ding","year":"2016","journal-title":"Evid. Based Complement. Alternat. Med."},{"key":"10.1016\/j.tips.2021.01.004_bb0625","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.cmet.2012.01.017","article-title":"Fumarate is cardioprotective via activation of the Nrf2 antioxidant pathway","volume":"15","author":"Ashrafian","year":"2012","journal-title":"Cell Metab."},{"key":"10.1016\/j.tips.2021.01.004_bb0630","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ejphar.2008.02.038","article-title":"Dimethyl fumarate, a small molecule drug for psoriasis, inhibits nuclear factor-\u03baB and reduces myocardial infarct size in rats","volume":"586","author":"Meili-Butz","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.tips.2021.01.004_bb0635","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2174\/1389200033489253","article-title":"Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist","volume":"4","author":"Beaumont","year":"2005","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.tips.2021.01.004_bb0640","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102335","article-title":"Monomethyl fumarate has better gastrointestinal tolerability profile compared with dimethyl fumarate","volume":"45","author":"Wynn","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.tips.2021.01.004_bb0645","series-title":"Tecfidera (Dimethyl Fumarate) - Highlights of Prescribing Information","author":"FDA","year":"2013"},{"key":"10.1016\/j.tips.2021.01.004_bb0650","doi-asserted-by":"crossref","first-page":"p1.403","DOI":"10.1212\/WNL.90.15_supplement.P1.403","article-title":"Relative bioavailability of monomethyl fumarate after administration of ALKS 8700 and dimethyl fumarate in healthy subjects","volume":"90","author":"Wehr","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2021.01.004_bb0655","doi-asserted-by":"crossref","first-page":"p1.188","DOI":"10.1212\/WNL.82.10_supplement.P1.188","article-title":"Steady state pharmacokinetics of formulations of XP23829, a novel prodrug of monomethyl fumarate (MMF), in healthy subjects","volume":"82","author":"Lissin","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2021.01.004_bb0660","series-title":"Skilarence","author":"European Medicines Agency","year":"2017"},{"key":"10.1016\/j.tips.2021.01.004_bb0665","series-title":"Vumerity (Diroxymel Fumarate) - Highlights of Prescribing Information","author":"FDA","year":"2013"}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614721000079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614721000079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T09:10:50Z","timestamp":1759050650000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614721000079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":133,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0165614721000079"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2021.01.004","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging Therapeutic Applications for Fumarates","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2021.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}